Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVLida Kalmanti, Linda Heinrich, Benjamin Hanfstein et al.|Leukemia|2015Cited by 274
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)Nicolaus Kröger, Théo de Witte, Simona Iacobelli et al.|Journal of Clinical Oncology|2017Cited by 248
A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myelomaIngmar Bruns, Guido Kobbe, Ulrich Steidl et al.|Transfusion|2005Cited by 68